Login to Your Account


Evolving standard of care

While breakthroughs in cancer treatments tend to come in incremental steps, payers in the U.S. cannot continue to pay breakthrough prices for incremental improvements in cancer drugs, two scientists with the National Cancer Institute (NCI) said after finding no rationale for the hefty prices of new cancer drugs. more »


Opinion


Partners in Focus